Trials / Completed
CompletedNCT00783341
Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GAP-134 | |
| DRUG | placebo |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-10-31
- Last updated
- 2009-07-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00783341. Inclusion in this directory is not an endorsement.